2022. June. 20.

This is an article on Cursus Bio, Inc. SYP is providing investment and commercialization support.

[Press Nine] Cursor Bio, a subsidiary of IQR, announced on the 17th that it announced the development of microneedle/bullet-type drugs at the "1st Promising Bio-venture and Startup Investment Forum 2022" hosted by K-BD Group in Kintex, Ilsan, on the 16th.

Hosted by the Korea New Drug Development Research Association and co-hosted by the K-BD Group and the Ajou Advanced Medical Bio Research Institute, the investment forum is designed to provide investment institutions such as domestic pharmaceutical, bio-companies and venture capital with opportunities for win-win cooperation and information exchange.

Cursus Bio's microneedle platform technology is based on the application of an inter-locking structure that overcomes the limitations of not being able to deliver quantitative drugs due to the characteristics of existing microneedles.

Cursus Bio has secured high-dose drug installation and skin low irritability by poppam using quantitative drug delivery technology based on technology to prevent deviation of key MicroLockTM technologies. Through this, it has expanded from cosmetics to DDS-improved new drug pipelines and is currently conducting research on peptide drugs (Lira Glutide, teriparatide, etc.) and biovaccines.

During the year since the company's establishment, it has secured eight patents and researched and developed cosmetics products for MicroDiamond cosmetic patches (improving eye wrinkles, whitening, skin wrinkles, acne, etc.) along with whitening, skin wrinkles, acne, etc.).

This year, Cursbio plans to complete preliminary experiments on liraglutide peptide drugs, which form a market of 5 trillion won in obesity diabetes treatments, to produce tangible results.

Based on the core technology of MicroLockTM, which enables high-dose quantitative drug transmission, we want to further develop excellent drugs and value that have increased patient convenience due to self-administration of peptides and biopharmaceuticals that have been used as existing injections. 

Contents Scource :   http://www.press9.kr/news/articleView.html?idxno=51871